Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Skin discolouration
Clinical narrative: This case was reported by a other health professional and described the occurrence of injection site pain in a 67-year-old female patient who received SHINGRIX. Previously administered products included ZOSTAVAX. On 25th January 2018, the patient received the 1st dos of SHINGRIX (subcutaneous). In January 2018, less than a week after receiving SHINGRIX, the patient experienced injection site erythema, malaise, headache and chills. On 25th January 2018, the patient experienced injection site pain and inappropriate route of vaccination. In January 2018, the outcome of the injection site pain was recovered/resolved. On an unknown date, the outcome of the injection site erythema, malaise, headache and chills were recovered/resolved and the outcome of the inappropriate route of vaccination was unknown. It as unknown if the reporter considered the injection site pain, injection site erythema, malaise, headache and chills to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported, but it could be 66 or 67 year old. The patient went to a pharmacy on 25th January 2018, in order to get a dose of the new shingles vaccine. The patient work in healthcare fields and have family members who had severe shingles. The patient received ZOSTAVAX in the past and wanted to get the new shingles vaccine as soon as it was available and thus went to their local pharmacy. The patient specifically asked the pharmacist at the pharmacy if they would get the new shingles vaccine and the patient was told yes. The patient was given a vaccine information sheet (VIS) for ZOSTAVAX. The pharmacist administered the vaccine subcutaneously (SQ) to the patient (patient was certain it was administered SQ), which led to inappropriate route of vaccine administration. The patient said, SHINGRIX was painful. The patient was given a pharmacy receipt and paperwork saying the vaccine administered was a one dose vaccine they were never instructed of the need for a 2nd dose to be given 2 to 6 months later. The patient had vey painful at injection site which started immediately after vaccination and lasted for total 4 days. The patient had redness at injection site, maximum 2 by 3 inches which lasted for total 4 days. The patient also experienced malaise, headache and chills for days 2-3. The reporter was aware SHINGRIX was to be administered intramuscularly, the reporter did research on internet and accessed the ZOSTER study that reported local and general adverse events from that study of SHINGRIX intramuscular compared with SHINGRIX SQ. The reporter subsequently spoke to another pharmacist at the pharmacy, to mention, the patient's experience and that patient received SHINGRIX SQ, was not instructed to come back for a 2nd dose, and was given a ZOSTAVAX VIS. The reporter was given the name of one of the pharmacist at pharmacy to contact but eh reporter had not contacted the pharmacist. The reporter reported the adverse event to VAERS on 4th February 2018. The reporter was provided (by his public health official contact) the name of vaccine safety office at Centers for Disease Control and Prevention (CDC). The reporter planned to contact that person today at CDC. The reporter told that, the patient plan to get the 2nd dose of SHINGRIX, between 2 to 6 months after 1st dose. The reporter was planned to check at the time of vaccination if the vaccine was kept 2 to 6 degree C, administered intramuscular and given materials specific to SHINGRIX. This case was linked to US2018GSK019497, reported by the same reporter.